Heart failure is now recognised as a major and escalating public health problem in industrialised countries with ageing populations. Any attempt to describe the epidemiology, aetiology, and prognosis of heart failure, however, must take account of the difficulty in defining exactly what heart failure is. Though the focus of this article is the symptomatic syndrome it must be remembered that as many patients again may have asymptomatic disease that might be legitimately labelled “heart failure” — for example, asymptomatic left ventricular systolic dysfunction. More comprehensive reviews of the epidemiology and associated burden of heart failure have been published by McMurray and colleagues and more recently by Cowie and colleagues.

Data relating to the aetiology, epidemiology and prognostic implications of heart failure are principally available from five types of studies:

- Cross sectional and longitudinal follow up surveys of well defined populations. These have almost exclusively focused on those individuals with clinical signs and symptoms indicative of chronic heart failure.
- Cross sectional surveys of individuals who have been medically treated for signs and symptoms of heart failure within a well defined region.
- Echocardiographic surveys of individuals within a well defined population to determine the presence of left ventricular systolic dysfunction.
- Nation wide studies of annual trends in heart failure related hospitalisation identified on the basis of diagnostic coding at discharge.
- Comprehensive clinical registries collected in conjunction with clinical trials. These include a large proportion of individuals who were identified on the basis of having both impaired left ventricular systolic dysfunction and signs and symptoms of heart failure.

Within the context of the specific limitations of the type of data available from these studies, the current understanding of the aetiology, epidemiology, and prognostic implications of chronic heart failure are discussed here.

### Table 1: Reported prevalence of heart failure

<table>
<thead>
<tr>
<th>Study</th>
<th>Location</th>
<th>Overall prevalence rate</th>
<th>Prevalence rate in older age group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surveys of treated patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCGP (1986)</td>
<td>UK national data</td>
<td>3/1000</td>
<td></td>
</tr>
<tr>
<td>RCGP (1986)</td>
<td>Rural cohort, USA</td>
<td>9-10/1000</td>
<td></td>
</tr>
<tr>
<td>Mair et al (1994)</td>
<td>Rochester, UK</td>
<td>3/1000 (&lt; 75 years)</td>
<td></td>
</tr>
<tr>
<td>RCGP (1995)</td>
<td>Liverpool, UK</td>
<td>15/1000</td>
<td></td>
</tr>
<tr>
<td>Clarke et al (1995)</td>
<td>UK national data</td>
<td>9/1000</td>
<td></td>
</tr>
<tr>
<td>Population screening</td>
<td></td>
<td>8-16/1000</td>
<td></td>
</tr>
<tr>
<td>Droller and Pemberton (1953)</td>
<td>Sheffield, UK</td>
<td>–</td>
<td>30-50/1000 (&gt; 65 years)</td>
</tr>
<tr>
<td>Garrison et al (1966)</td>
<td>Georiga, USA</td>
<td>21/1000 (45-74 years)</td>
<td>35/1000 (&gt; 65 years)</td>
</tr>
<tr>
<td>Framingham (1972)</td>
<td>Framingham, USA</td>
<td>3/1000 (&lt; 63 years)</td>
<td>2/1000 (&gt; 60-79 years)</td>
</tr>
<tr>
<td>Landahl et al (1984)</td>
<td>Sweden (males only)</td>
<td>3/1000 (&lt; 75 years)</td>
<td>80-170/1000 (&gt; 67 years)</td>
</tr>
<tr>
<td>NHANES (1992)</td>
<td>USA national data</td>
<td>20/1000</td>
<td>80/1000 (&gt; 65 years)</td>
</tr>
<tr>
<td>Cardiovascular health study</td>
<td></td>
<td>20/1000</td>
<td></td>
</tr>
<tr>
<td>(1993)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RCGP (1995)</td>
<td>UK national data</td>
<td>9/1000 (25-74 years)</td>
<td>74/1000 (&gt; 65-74 years)</td>
</tr>
</tbody>
</table>
to 28 cases/1000 in those aged over 65 years. However, objective investigation of left ventricular function had been undertaken in less than one third of these patients. Using similar methods, Mair and colleagues identified a total of 266 cases of heart failure from 17 400 patients within two general practices in Liverpool. Undertaken in 1994, the overall prevalence rate was 15 cases/1000 patients with 80 cases/1000 in those aged ≥ 65 years.

More recently, Clarke and colleagues reported an even larger survey of heart failure based on similar methods and including analysis of prescription of loop diuretics for all residents of the English county of Nottinghamshire. They estimated that between 13 017 and 26 214 patients had been prescribed frusemide (furosemide) in this region of central England. Case note review of a random sample of those patients receiving such treatment found that 56% were being treated for heart failure. On this basis they calculated an overall prevalence rate of 8–16 cases/1000. Once again, heart failure prevalence increased with advancing age with the rate increasing to between 40–60 cases/1000 among those aged ≥ 70 years.

Population studies based on clinical criteria.

There are now many population studies of heart failure and only some can be reviewed here. An early into the Framingham study, 17 of 5209 persons (3 cases/1000) screened for heart failure on the basis of clinical criteria were thought to have heart failure; all were less that 63 years of age. After 34 years follow up, prevalence rates increased as the cohort aged. The estimated prevalence of heart failure in the age groups 50–59, 60–69, 70–79, and ≥ 80 years was 8, 23, 49, and 91 cases/1000 persons respectively. NHANES-I (national health and nutrition examination survey) reported the heart failure prevalence rate within the US population. Based on self reporting, and a clinical scoring system, this study screened 14 407 persons of both sexes, aged 25–47 years, between 1971 and 1975, with detailed evaluation of only 6913 subjects and reported a prevalence rate of 20 cases/1000.

The Rotterdam study in the Netherlands, though examining individuals aged 55–74 years, reported similar findings. Overall the prevalence of left ventricular systolic dysfunction, defined in this case as fractional shortening of ≤ 25%, was 5.5% in men and 2.2% in women.

The Helsinki ageing study describes clinical and echocardiographic findings in 501 subjects aged 75–86 years. The prevalence of heart failure, based on clinical criteria, was 8.2% overall (41 of 501) and 6.8%, 10%, and 8.1% in those aged 75, 80, and 85 years, respectively. These individuals had a high prevalence of moderate or severe mitral or aortic valve disease (51%), ischaemic heart disease (54%), and hypertension (54%). However, of the 41 subjects with “heart failure” only 11 (28%) had significant left ventricular systolic dysfunction (diagnosed by the combined presence of fractional shortening < 25% and left ventricular dilation), and in 20 cases no echocardiographic abnormality was identified. Of the 460 without symptoms of heart failure 43 (9%) also had left ventricular systolic dysfunction. The overall prevalence of all grades of dysfunction was 7.5% (95% confidence interval (CI) 5.8% to 9.5%). Prevalence of left ventricular dysfunction doubled between the ages of 70–74 years and > 80 years.

Prevalence of left ventricular systolic dysfunction

In only a few of the two types of prevalence study described above was objective evidence of cardiac dysfunction obtained. Consequently, it is unclear whether all patients really had heart failure and, if they did, what the cause of heart failure was. There have, however, been four recent estimates of the population prevalence of left ventricular systolic dysfunction as determined by echocardiography emanating from Scotland, the Netherlands, England, and Finland.

The Scottish study targeted a representative cohort of 2000 persons aged 25–74 years living north of the River Clyde in Glasgow. Of those selected 1640 (83%) underwent a detailed assessment of their cardiovascular status and underwent echocardiography. Left ventricular systolic dysfunction was defined as a left ventricular ejection fraction (LVEF) ≤ 30%. The overall prevalence of left ventricular systolic dysfunction using this criterion was 2.9%. Concurrent symptoms of heart failure were found in 1.5% of the cohort, while the remaining 1.4% were asymptomatic. Prevalence was both greater in men and increased with age: in men aged 65–74 years it was 6.4% and in age matched women 4.9%.

The Rotterdam study in the Netherlands, though examining individuals aged 55–74 years, reported similar findings. Overall the prevalence of left ventricular systolic dysfunction, defined in this case as fractional shortening of ≤ 25%, was 5.5% in men and 2.2% in women. The Helsinki ageing study describes clinical and echocardiographic findings in 501 subjects (367 female) aged 75–86 years. The prevalence of heart failure, based on clinical criteria, was 8.2% overall (41 of 501) and 6.8%, 10%, and 8.1% in those aged 75, 80, and 85 years, respectively. These individuals had a high prevalence of moderate or severe mitral or aortic valve disease (51%), ischaemic heart disease (54%), and hypertension (54%). However, of the 41 subjects with “heart failure” only 11 (28%) had significant left ventricular systolic dysfunction (diagnosed by the combined presence of fractional shortening < 25% and left ventricular dilation), and in 20 cases no echocardiographic abnormality was identified. Of the 460 without symptoms of heart failure 43 (9%) also had left ventricular systolic dysfunction. The overall prevalence of all grades of dysfunction was 7.5% (95% confidence interval (CI) 5.8% to 9.5%). Prevalence of left ventricular dysfunction doubled between the ages of 70–74 years and > 80 years.

Preserved left ventricular systolic function

One of the most controversial issues pertaining to the subject of heart failure at present is the occurrence of the syndrome in patients with preserved left ventricular systolic function (and no other obvious cause, such as valve disease). A full discussion of this topic is beyond the scope of this article. There are, however, two recent studies of this type of heart failure. The Olmsted county study, Minnesota, found that 43% of patients with chronic heart failure had an LVEF ≥ 50%. Similarly, the Framingham investigators found that 51% of their cohort with heart failure had an LVEF of ≥ 50% (see also Helsinki ageing study above).
Incidence

There is much less known about the incidence than the prevalence of heart failure. Table 2 shows reported incidence rates from the largest population based studies. The most detailed incidence data emanate from the Framingham heart study.1 Like other population based prevalence studies heart failure was defined according to a clinical scoring system. The only “cardiac” investigation was chest radiography. At 34 years follow up, the incidence of heart failure was approximately 2 new cases/1000 in persons aged 45–54 years, increasing to 40 new cases/1000 in men aged 85–94 years. Using similar criteria, the study of men born in 1913 reported incidence rates of “manifest” heart failure of 1.5, 4.3, and 10.2 new cases/1000 in men aged 50–54, 55–60, and 61–67 years, respectively.6,7 The Rochester epidemiology project also reported the incidence of heart failure in a US population during 1981 in persons aged 0–74 years.6,7 The annual incidence was 1.1 new cases/1000. Once again incidence was higher in men compared to women (1.57 v 0.71 cases/1000, respectively). It also increased with age, the rate of new cases increasing from 0.76/1000 in men aged 45–49 years to 1.8/1000 in men aged 65–69 years.

The most recent incidence study was reported by Cowie and colleagues from the Hillingdon district of London with a population of approximately 150,000.8 In a 15 month period, 122 patients were referred to a special heart failure clinic. This represented an annual referral rate of 6.5/1000 population. Using a broad definition of heart failure, only 29% of these patients were clearly diagnosed as having heart failure (annual incidence 1.85/1000 population).

Heart failure admissions

A different type of epidemiological information comes from reports of heart failure related hospital admissions on a country to country basis; however, these also need to be interpreted with some caution because of their retrospective nature and variations in coding practices and changing admission thresholds over time. Figure 1 shows the reported hospitalisation rates from Scotland,4 Spain, the USA, Sweden, New Zealand, and the Netherlands for the period 1978 to 1993. As such, hospitalisation for heart failure appears to be a growing problem on a global scale. For example, studies undertaken in the UK suggest that in the early 1990s 0.2% of the population were hospitalised for heart failure per annum and that such admissions accounted for more than 5% of adult general medicine and geriatric hospital admissions—outnumbering those associated with acute myocardial infarction.4 In the USA heart failure continues to be the most common cause of hospitalisation in people over the age of 65 years.7

An admission for heart failure is frequently prolonged and in many cases followed by readmission within a short period of time. For example, in the UK the mean length of stay for a heart failure related admission in 1990 was 11.4 days on acute geriatric wards and 28.5 days on acute medical wards. Within the UK about one third of patients are readmitted within 12 months of discharge, while the same proportion are reportedly readmitted within six months in the USA.8,9 Such readmission rates are usually higher than the other major causes of hospitalisation, including stroke, hip fracture, and respiratory disease. Moreover, although there is evidence to suggest that an increasing number of heart failure patients are surviving a heart failure related hospital admission, there is a parallel decrease in the number of patients who are discharged on an independent basis to their own homes. On a sex specific basis, men tend to be younger than women when admitted for the first time with heart failure, but because of greater female longevity, the number of male and female admissions are roughly equal.

Cost of heart failure

In any health care system, hospital admissions represent a disproportionate component of total health care expenditure. Not surprisingly, considering the high rates of hospitalisation for heart failure and the ongoing treatment and care it requires, the overall management of heart failure requires a significant amount of health care expenditure in industrialised nations. Figure 2 shows that heart failure is reported to consume 1–2% of health care expenditure in a number of industrialised countries.1 Moreover, considering the increasing rates of hospitalisation it is likely that these reported estimates fall short of the current burden of heart failure.

Table 2: Reported incidence of heart failure.

<table>
<thead>
<tr>
<th>Study</th>
<th>Location</th>
<th>Incidence rate (whole population)</th>
<th>Incidence rate in older age groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remes et al (1992)</td>
<td>Eastern Finland</td>
<td>1–4/1000 (45–74 years)</td>
<td>8/1000 (&gt; 65 years)</td>
</tr>
<tr>
<td>Ho et al (1993)</td>
<td>Framingham, USA</td>
<td>2/1000</td>
<td>–</td>
</tr>
<tr>
<td>Rodehoffer et al (1995)</td>
<td>Rochester, USA</td>
<td>1/1000 (&lt; 75 years)</td>
<td>10/1000 (&gt; 65 years)</td>
</tr>
</tbody>
</table>

Figure 1: Comparison of heart failure admissions rates per annum (recorded hospital admissions/10,000 population at risk) in western developed countries 1978 to 1993. Adapted from data in McMurray et al.1
Aetiology of heart failure

In western developed countries, coronary artery disease, either alone or in combination with hypertension, seems to be the most common cause of heart failure. It is, however, very difficult to be certain what is the primary aetiology of heart failure in a patient with multiple potential causes (for example, coronary artery disease, hypertension, diabetes mellitus, atrial fibrillation, etc). Furthermore, even the absence of overt hypertension in a patient presenting with heart failure does not rule out an important aetiological role in the past, with normalisation of blood pressure as the patient develops pump failure. Even in those with suspected coronary artery disease the diagnosis is not always correct and in the absence of coronary angiography must remain presumed rather than confirmed. In this context, even coronary angiography has its limitations in identifying atherosclerotic disease.

The initial cohort of the Framingham heart study was monitored until 1965; hypertension appeared to be the most common cause of heart failure, being identified as the primary cause in 30% of men and 20% of women and a cofactor in a further 33% and 25%, respectively. Moreover, electrocardiographic evidence of left ventricular hypertrophy in the presence of hypertension carried an approximate 15 fold increased risk of developing heart failure. In the subsequent years of follow up, however, coronary heart disease became increasingly prevalent before the development of heart failure and, as the identified cause of new cases of heart failure, increased from 22% in the 1950s to almost 70% in the 1970s. During this period, the relative contribution of hypertension and valvar heart disease declined dramatically. Figure 3 is a summary of the changing association of coronary artery disease, hypertension, diabetes, and valvar heart disease with the subsequent development of heart failure over the period 1950 to 1987.

As such there was an approximate 5% and 30% decline in the prevalence per decade of hypertension during this period among men and women, respectively. The declining contribution of hypertension most probably reflects the introduction of antihypertensive treatment; the parallel decline in the prevalence of left ventricular hypertrophy supports this supposition. It is also probable that during this same period, progressively greater accuracy in determining the presence of coronary heart disease contributed to its increasing importance in this regard.

As noted above, however, any interpretation of the Framingham data has to consider the fact that heart failure was identified on clinical criteria alone and undoubtedly included individuals without associated left ventricular systolic dysfunction. Conversely, the large scale clinical trials have largely recruited patients who have reduced left ventricular ejection fractions and applied an extensive list of exclusion criteria. Table 3 is a summary of the most commonly attributed causes and associates of heart failure in a number of clinical trials and registries. As such it demonstrates that coronary artery disease appears to be the most common underlying cause of heart failure, consistent with the more recent Framingham experience.

---

**Common precursors of chronic heart failure**

- Coronary artery disease (for example, consequent upon acute myocardial infarction)
- Chronic hypertension
- Cardiomyopathy (for example, dilated, hypertrophic, alcoholic, and idiopathic)
- Valve dysfunction (for example, diseases of the aortic and mitral valve)
- Cardiac arrhythmias/conduction disturbance (for example, heart block and atrial fibrillation)
- Pericardial disease (for example, constrictive pericarditis)
- Infection (for example, rheumatic fever, Chagas disease, viral myocarditis, and HIV)

---

**Figure 2:** Cost of chronic heart failure compared with the total health expenditure in Sweden, the UK, France, the USA, the Netherlands, and New Zealand. The figures represent the component of hospital costs contributing to total expenditure quoted in the local currency and (in parentheses) as a proportion of total health care expenditure for that country. Adapted from data in McMurray et al.

**Figure 3:** Change in causal factors for heart failure in the Framingham heart study during the period 1950 to 1987. Adapted from data reported by Kannel WB et al.
The median follow up in these cohorts was 1061 and 1233 days, respectively. The mean age of the 1981 patients was 75 years rising to 77 years in 1991. The one year and five year mortality was, respectively, 28% and 66% in the 1981 cohort and 23% and 67% in the 1991 cohort. In other words, though the same diagnostic criteria used in the Framingham study were used in the Rochester project, the prognosis was somewhat better in the latter.

The only other large, representative, epidemiological study reporting long term outcome in patients with heart failure is the NHANES-I. The initial programme evaluated 14 407 adults aged 25 and 74 years in the USA between 1971 and 1975. Follow up studies were carried out in 1982-84 and again in 1986 (for those aged > 55 years and alive during the 1982-84 review). The estimated 10 year mortality in subjects aged 25–74 years with self reported heart failure was 42.8% (49.8% in men and 36% in women). Mortality in those aged 65–74 years was 65.4% (71.8% and 59.5% in men and women, respectively). These mortality rates are considerably lower than those observed in Framingham. The patients in NHANES-I were non-institutionalised and their heart failure was self reported. Follow up was incomplete. NHANES-I was also carried out in a more recent time period than Framingham when prognosis in heart failure patients may have improved. Framingham investigators in 1993 looked at patients developing heart failure in the period 1948 to 1988 and the Rochester investigators in the period 1981 to 1991. In both of these studies no temporal change in prognosis was identified.

All three of these studies describe a mixed population of patients, some of whom had systolic left ventricular dysfunction and others who did not. The true contribution of heart failure to overall mortality or coronary artery disease related mortality is almost

### Prognosis

Heart failure, irrespective of whether it has been detected on the basis of being actively treated (for example, during a hospital admission) or in otherwise asymptomatic individuals, is a lethal condition.

There are some data to suggest that heart failure related mortality is comparable to that of cancer. For example, in the original and subsequent Framingham cohort, the probability of someone with a diagnosis of heart failure dying within five years was 62% and 75% in men and 38% and 42% in women, respectively. In comparison, five year survival for all cancers among men and women in the US during the same period was approximately 50%. The general applicability of these data is, however, limited by the few events recorded overall, the relative homogeneity of the Framingham population, and the exclusion of older individuals. The Rochester epidemiology project has also described the prognosis in 107 patients presenting to associated hospitals with new onset heart failure in 1981, and 141 patients presenting in 1991. The median follow up in these cohorts was 1061 and 1233 days, respectively. The mean age of the 1981 patients was 75 years rising to 77 years in 1991. The one year and five year mortality was, respectively, 28% and 66% in the 1981 cohort and 23% and 67% in the 1991 cohort. In other words, though the same diagnostic criteria used in the Framingham study were used in the Rochester project, the prognosis was somewhat better in the latter.

The only other large, representative, epidemiological study reporting long term outcome in patients with heart failure is the NHANES-I. The initial programme evaluated 14 407 adults aged 25 and 74 years in the USA between 1971 and 1975. Follow up studies were carried out in 1982-84 and again in 1986 (for those aged > 55 years and alive during the 1982-84 review). The estimated 10 year mortality in subjects aged 25–74 years with self reported heart failure was 42.8% (49.8% in men and 36% in women). Mortality in those aged 65–74 years was 65.4% (71.8% and 59.5% in men and women, respectively). These mortality rates are considerably lower than those observed in Framingham. The patients in NHANES-I were non-institutionalised and their heart failure was self reported. Follow up was incomplete. NHANES-I was also carried out in a more recent time period than Framingham when prognosis in heart failure patients may have improved. Framingham investigators in 1993 looked at patients developing heart failure in the period 1948 to 1988 and the Rochester investigators in the period 1981 to 1991. In both of these studies no temporal change in prognosis was identified.

All three of these studies describe a mixed population of patients, some of whom had systolic left ventricular dysfunction and others who did not. The true contribution of heart failure to overall mortality or coronary artery disease related mortality is almost
Future burden of heart failure

Despite a decline in age adjusted mortality from coronary heart disease (CHD) in developed countries overall, the number of patients with chronic CHD is increasing. This is principally the result of two separate trends. Firstly, the proportion of elderly in the population is increasing rapidly and these subjects have the highest incidence of CHD and hypertension. Secondly, survival in those with coronary artery disease is improving. In particular, it has been shown that survival after acute myocardial infarction has increased notably over the past decade, at least in part because of better medical treatment. As coronary artery disease is the most powerful risk factor for heart failure (and its most important precursor) it is likely that the aforementioned trends will lead to an increase its future prevalence. Chronic heart failure may, therefore, become a more common manifestation of chronic heart disease and contribute to many more deaths. Two formal projections of the future burden of heart failure have been undertaken in respect to the Netherlands and Australia. For example, an analysis of demographic trends in the Netherlands has predicted that the prevalence of heart failure caused by coronary heart disease will rise by approximately 70% from 1985 to 2010.

**Summary**

- Heart failure represents a major and escalating public health problem.
- The overall prevalence of clinically identified heart failure is estimated to be 3–20 cases/1000 population, but rises to >100 cases/1000 population in those aged >65 years.
- Prevalence of confirmed left ventricular systolic dysfunction also increases with age and is more common in men. However, these rates are far less than reported for the syndrome of heart failure.
- The overall annual incidence of clinically overt heart failure in middle aged men and women is approximately 0.1–0.2%.
- Although reported incidence rates are higher in men than women, greater longevity in women tends to balance overall prevalence rates on a sex specific basis.
- Heart failure admission rates appear to be steadily increasing in all industrialised countries, especially among older individuals. Overall, annual admission rates for 1990 ranged from 10–40 admissions/10,000 population and increased to >75 admissions/10,000 population in those aged >65 years.
- The cost of managing heart failure in the early 1990s was estimated to be 1–2% of total health care expenditure. Because hospital care consumes a significant proportion of this expenditure, and rates of heart failure related hospitalisation have probably risen, this may be an underestimate of the current cost of heart failure.
- Heart failure is associated with an approximately 60% mortality rate within five years of diagnosis.
- The combination of increasing survival post acute myocardial infarction and increased longevity in western developed nations is likely to lead to an increase in the overall prevalence of heart failure.


A survey of heart failure related hospitalisations in the USA during the period 1985 to 1995. It represents the most up to date report from an industrialised nation.


Using data from the long term surveillance of the Framingham cohorts, an important overview of the changing epidemiology and aetiology of heart failure.


A clinical trial based registry that contains data from 105 study centres in eight countries in North America and Europe.


Another follow up report of the Framingham study describing extremely poor survival rates in those individuals diagnosed with chronic heart failure.


The first population based modelling exercise of its kind, this study estimated the future prevalence and associated burden of chronic heart failure in the Netherlands.